Clarification follows market speculation and stock price movement

Lund, Sweden - 30 September 2010 - Following stock price movement on 29 September, BioInvent International AB (OMXS: BINV) wishes to communicate the status of its TB-403 (RG7334) programme, in development with Roche. 

Roche plans to initiate the next phase of TB-403 development in early 2011. A phase Ib/II trial of TB-403 in combination with Avastin in Glioblastoma Multiforme patients will commence Q1 2011.  

A DCE-MRI imaging study of TB-403 that was commenced by Roche earlier this year has been stopped as per protocol.
 

-- END --

Notes to Editors: 

About BioInvent
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics. 

The company's competitive position is underpinned by an in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe, UCB and XOMA. 

More information is available at www.bioinvent.com (http://www.bioinvent.com).

For further information, please contact: 

BioInvent International AB
Svein Mathisen
President & CEO
Tel: +46 (0)46-286 85 67
Mobile: +46 (0)708-97 82 13
E-mail: [email protected] ([email protected]) 
Cristina Glad
Executive Vice President
Tel: +46 (0)46-286 85 51
Mobile: +46 (0)708-16 85 70
E-mail: [email protected] ([email protected])

College Hill (media enquiries)
Katja Toon, Justine Lamond, Anastasios Koutsos
Tel: +44 (0)20 7866 7857
E-mail: [email protected] ([email protected])

Erik Clausen (US)
Tel: +1 415-230-5385
E-mail: [email protected] ([email protected])

BioInvent International AB (publ)
Co. reg. No. 556537-7263,
Address:  Sölvegatan 41 
Mailing address: SE-223 70 LUND
Tel: +46 (0)46 286 85 50
[email protected] ([email protected])  
www.bioinvent.com (http://www.bioinvent.com/)   

Legal disclaimer
This press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release. 

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.20 a.m. CET, on 30 September, 2010.